📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. (2024)

First Author: EMPA-KIDNEY Collaborative Group

Attributed to: Adiposity and kidney disease: observations from large blood-based prospective cohorts across a wide range of different populations funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-8587(23)00321-2

PubMed Identifier: 38061371

Publication URI: http://europepmc.org/abstract/MED/38061371

Type: Journal Article/Review

Volume: 12

Parent Publication: The lancet. Diabetes & endocrinology

Issue: 1

ISSN: 2213-8587